Company news
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) news
Edgewise Therapeutics, Inc. news releases on 6ix. Latest, May 11, 2022: Edgewise Therapeutics Reports First Quarter 2022 Financial Results
Press releases — page 3
Edgewise Therapeutics Reports First Quarter 2022 Financial Results
May 10, 2022
Edgewise-Funded Natural History Trial of Becker Muscular Dystrophy (BMD) Now Enrolling
April 13, 2022
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2022 Annual MDA Clinical and Scientific Conference
March 7, 2022
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
February 23, 2022
Edgewise Therapeutics to Participate at SVB Leerink 11th Annual Global Healthcare Conference on February 16
February 1, 2022
Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)
January 4, 2022
Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study
December 14, 2021
Edgewise Therapeutics to Participate at Evercore ISI 4th Annual HEALTHCONx Conference on December 2
November 16, 2021
Edgewise Therapeutics Reports Third Quarter 2021 Financial Results
November 9, 2021
Edgewise Therapeutics Announces Positive Topline Results from the EDG-5506 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HVs) and Doses First Becker Muscular Dystrophy (BMD) Patients
October 27, 2021
Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event on September 23
September 13, 2021
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Individuals with Becker Muscular Dystrophy (BMD)
August 15, 2021
Edgewise Therapeutics Reports Second Quarter 2021 Financial Results
August 8, 2021
Edgewise Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 11
August 3, 2021
Edgewise Therapeutics to Present at the PPMD Annual Conference and the New Directions in Biology and Disease of Skeletal Muscle Conference
June 21, 2021
Edgewise Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
May 31, 2021
Edgewise Therapeutics Reports First Quarter 2021 Financial Results and Recent Highlights
May 12, 2021
Edgewise Therapeutics Announces Publication of Data Demonstrating the Elevation of Fast but Not Slow Skeletal Muscle Fiber Injury Biomarkers in the Circulation of Patients with Becker and Duchenne Muscular Dystrophy
May 3, 2021
Edgewise Therapeutics Appoints Joanne Donovan, M.D., Ph.D., as Chief Medical Officer
April 26, 2021
Edgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
March 29, 2021
Edgewise Therapeutics Announces Pricing of Initial Public Offering
March 24, 2021